Refers to carboxamide derivatives and urea compounds of formula (i) wherein R1 is H, C (= o) Oh, Oh, NH2, among others R2 is H, F, CN, CF3, among others R3 is H or an aliphatic residue (C1 - C10) n is 1 4 R3A is H or an aliphatic residue (c1-c4) R4A is H, an aliphatic residue (c1-c4), cicloalifatic (C3 and C6), among others and it is o, s or N - CN Z is n or C - r4b,Where r4b is H or an aliphatic residue (c1-c4) T1 is n or C - R5, R6 U1 is n or C V is n or C - U2 R7, R8 is n or C T2 is n or C - R9, R5, R6, R7, R8 and R9 each h, F, NO2, CN, cfh2, among others.Preferred compounds are: N - ((1 - (3-chlorophenyl) - 3 - (trifluoromethyl) - 1H pyrazole - 5 - yl) methyl) - 2 - (pyridin-2-yl) acetamide n - (3 - (Tert Butyl) - 1 - (3-chlorophenyl) - 1H pyrazole - 5 - yl) methyl) - 2 - (pyridin-2-yl) propanamide among others. It also relates to a Pharmaceutical composition.These compounds are useful as vanilloid receptor ligands in the treatment of Pain, Parkinsons disease, irritable bowel syndromeSE REFIERE A COMPUESTOS DERIVADOS DE CARBOXAMIDA Y UREA DE FORMULA (I) DONDE R1 ES H, C(=O)-OH, OH, NH2, ENTRE OTROS R2 ES H, F, CN, CF3, ENTRE OTROS R3 ES H O UN RESIDUO ALIFATICO(C1-C10) n ES DE 1 A 4 R3a ES H O UN RESIDUO ALIFATICO(C1-C4) R4a ES H, UN RESIDUO ALIFATICO(C1-C4), CICLOALIFATICO(C3-C6), ENTRE OTROS Y ES O, S O N-CN Z ES N O C-R4b, EN DONDE R4b ES H O UN RESIDUO ALIFATICO(C1-C4) T1 ES N O C-R5 U1 ES N O C-R6 V ES N O C-R7 U2 ES N O C-R8 T2 ES N O C-R9 R5, R6, R7, R8 Y R9 SON CADA UNO H, F, NO2, CN, CFH2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-((1-(3-CLOROFENIL)-3-(TRIFLUOROMETIL)-1H-PIRAZOL-5-IL)METIL)-2-(PIRIDIN-2-IL)ACETAMIDA N-((3-TER-BUTIL-1-(3-CLOROFENIL)-1H-PIRAZOL-5-IL)METIL)-2-(PIRIDIN-2-IL)PROPANAMIDA ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR VANILLOIDE SIENDO UTILES EN EL TRATAMIENTO DE DOLOR, ENFERMEDAD DE PARKINSON, SINDROME DEL INTESTINO IRRITABLE
